welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Capricor Therapeutics announced today that it will meet with the U.S. Food and Drug Administration (FDA) in December to discuss clinical trial design, surrogate or intermediate endpoints and manufacturing processes for CAP-1002, Capricor’s novel cell therapy. Currently, patients are being enrolled in the HOPE-2 clinical trial, which is investigating CAP-1002 as a therapy for the treatment of Duchenne muscular dystrophy.
The in-person meeting is part of the expedited review process afforded to Capricor for its CAP-1002 product candidate after being granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA in February 2018. The FDA grants the RMAT designation to regenerative medicine therapies intended to treat a serious condition and for which preliminary clinical evidence indicates a potential to address unmet medical needs for that condition.
rareRelated
-
Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular DisordersThe hypothesis is that a mechanical insu...
-
Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)The purpose of this study is to establis...
-
Pathway Key to Muscle Regeneration Doesn’t Work as It Should in Duchenne, Study FindsThe Hippo signaling pathway — a key re...
-
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...
-
A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
-
A Study of Tadalafil for Duchenne Muscular DystrophyThe main purpose of this study is to det...
-
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical tri...Duchenne muscular dystrophy (DMD) is an ...
-
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular D...FibroGen, Inc., a leading biopharmaceu...
-
Hope in Translation: Bringing Gene Therapy to the ClinicIn 1987, scientists first uncovered the ...
